Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

ter ended June 30, 2013. Non-GAAP net income for the quarter ended September 30, 2012 was $78.8 million, or $1.13 and $1.06 net income per basic and diluted share, respectively. Non-GAAP net income reported for the nine months ended September 30, 2013 was $43.3 million, or $0.60 and $0.57 net income per basic and diluted share, respectively, compared to non-GAAP net income of $54.4 million or $0.79 and $0.74 net income per basic and diluted share, respectively, for the nine months ended September 30, 2012. See "Use of Non-GAAP Financial Measures" below for a description of our non-GAAP measures. A reconciliation between certain generally accepted accounting principles ("GAAP") and non-GAAP measures is provided at the end of this press release.

GAAP net income for the quarter ended September 30, 2013 was $42.3 million, or $0.58 and $0.55 net income per basic and diluted share, respectively, compared to GAAP net income of $12.4 million, or $0.17 and $0.16 net income per basic and diluted share, respectively, for the quarter ended June 30, 2013. For the quarter ended September 30, 2012, GAAP net income was $75.6 million, or $1.09 and $1.02 net income per basic and diluted share, respectively. For the nine months ended September 30, 2013, GAAP net income was $2.8 million, or $0.04 net income per basic and diluted share, compared to GAAP net income of $45.9 million, or $0.66 and $0.62 net income per basic and diluted share, respectively, for the nine months ended September 30, 2012. Included in GAAP net income for the nine months ended September 30, 2013 and September 30, 2012 was stock-based compensation expense of $40.6 million and $8.5 million, respectively.

To date, the Company has earned milestone payments of $275 million under the Agreement. In addition to the $75 million, representing regulatory milestones earned under the Agreement during the three months ended September 30, 2013, the Company also earned four development milestone payments from Jans
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Come fall, many children, teenagers, and even ... want to be for Halloween. And, a number of ... contact lenses bought without a prescription. Halloween, ... purchase and wear contact lenses without a prescription. According ... consumer survey, 17 percent of Americans have worn ...
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... and DUBLIN , Sept. ... or the "Company"), a biotechnology company pioneering the manufacturing ... of innovative therapies for cancer, HIV/AIDS, opportunistic infections and ... its shareholders from CEO Noreen Griffin The letter follows: ... (the "Company" or "TNIB") received a number of calls ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8
... 15 Tolerx, Inc., a,biopharmaceutical company engaged in ... treatment of immune-mediated diseases, announced today,the successful completion ... a novel,humanized anti-CD4 monoclonal antibody (MAb), in subjects ... study was designed to,assess the safety, tolerability, and ...
... System Runs ,Heart Model of the Future, ... To Insight, SUNNYVALE, Calif., Jan. 15 In the quest ... Montreal (UdM) have run the largest mathematical simulation of a heart,ever ... system from SGI (Nasdaq: SGIC ). The new UdM model ...
Cached Medicine Technology:Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 2Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 3Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 2Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 3Universite de Montreal Researchers Simulate World's Largest Heart Model Using SGI Technology 4
(Date:9/30/2014)... 2014 All on Four dental ... persons who have received dental implants to vigilant in ... post. , The post, which can be found at ... if they don’t brush and floss diligently, they could ... their natural teeth: the bone will deteriorate and the ...
(Date:9/30/2014)... 2014 Youth Town’s annual BBQ/Music Festival ... to 2 p.m. at the Youth Town campus (3641 ... sponsors this family-oriented festival, which will offer music, food ... feature a car show, arts and crafts fair, music, ... games. Also, Lightning McQueen and Mater from the hit ...
(Date:9/30/2014)... 2014 “Biology and botany are ... Brickner, “and it’s about naming rights.” , In ... new on the Bryan William Brickner Blog, the ... Institutes of Health (PubMed). The post highlights five ... REM transitions, aging with THC, the wake-inducing effects ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 Top10inaction.com, ... main focus on ranking and reviewing all essential categories ... has officially announced the best liquid foundation at ... Serum Foundation is named as the best foundation of ... drugstore as well as high end brands, hence customers ...
(Date:9/30/2014)... East Longmeadow, Massachusetts (PRWEB) September 30, 2014 ... Excellence’, the Wingate of East Longmeadow facility has ... new Ventilator Program that combines advanced ... staff. This program is one of the only ... this type of care. The primary focus ...
Breaking Medicine News(10 mins):Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 3
... mobile computing and medication carts unveils TX11: a mobile computing cart ... ... OH (PRWEB) November 11, 2008 -- The Columbus, OH based medical ... newest in their line of mobile computing carts : the ...
... MOUNTAIN VIEW, Calif., Nov. 11 The 2008 ... Product,Innovation of the Year Award is presented to ... suppressant ingredient -,Slimaluma - for the global weight ... action, superior quality and safety,standards of Slimaluma have ...
... 10 Ready or not, the holiday season,is here. ... turkey and pies, merry-making eggnog and potato latkes,and then ... come Super Bowl,buffalo wings and Valentine,s Day chocolates to ... non-stop holiday cooking and,feasting., Enter Helene Phillips, the ...
... Nov. 10 TeamHealth Inc.,s parent,company, Team Finance ... quarter ended September 30, 2008., The Company ... services business line and substantially completed the disposal,of ... 2007. In accordance with,relevant accounting guidance, the results ...
... Of $9 million appropriated by,the Texas legislature to ... automated external defibrillators (AEDs), $3.5 million remains,unclaimed. Texas ... purchase under,the reimbursement program until the November 14, ... by lay people with CPR training,to resuscitate victims ...
... Increased risk of stroke a major issue in analysis of ... An analysis of 33 studies on drugs known as beta ... surgical procedure other than heart surgery. In fact, using beta ... stroke, the scientists say. , The researchers who conducted the ...
Cached Medicine News:Health News:Mobile Computing Carts Leader to Release New Clinical Computer Cart 2Health News:Gencor Pacific Group Picks Up Frost & Sullivan Global Appetite Suppressant and Satiety Ingredients Product Innovation of the Year Award 2Health News:Gencor Pacific Group Picks Up Frost & Sullivan Global Appetite Suppressant and Satiety Ingredients Product Innovation of the Year Award 3Health News:Tips for Maintaining Your Physique While Enjoying Your Favorite Treats 2Health News:Tips for Maintaining Your Physique While Enjoying Your Favorite Treats 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 2Health News:Team Finance LLC Announces Third Quarter 2008 Results 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 4Health News:Team Finance LLC Announces Third Quarter 2008 Results 5Health News:Team Finance LLC Announces Third Quarter 2008 Results 6Health News:Team Finance LLC Announces Third Quarter 2008 Results 7Health News:Team Finance LLC Announces Third Quarter 2008 Results 8Health News:Team Finance LLC Announces Third Quarter 2008 Results 9Health News:$3.5 Million in Reimbursements for Purchases of Automated External Defibrillators (AEDs) for Texas Schools Still Unclaimed With Deadline Approaching 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 3
0.25 mm diameter textured tip with protective guard....
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
... for perfect focus where it's needed - ... along with Keeler's wide angle light beam ... patient's pupil size, you will see the ... technology provides a longer life battery and ...
... individually adjusted for perfect focus where it's ... paper. This, along with Keeler's wide angle ... whatever the patient's pupil size, you will ... view. Lithium-ion technology provides a longer life ...
Medicine Products: